Ductal and lobular carcinoma: what separates them?

Both names may be paired with in situ or invasive. In situ disease remains within its structure of origin. Invasive disease has entered nearby breast tissue and has the capacity to spread to lymph nodes or other organs.

The pathologist identifies the carcinoma type by examining cells and their arrangement, sometimes supported by special stains. A report may use the term no special type for the common invasive carcinoma historically called invasive ductal carcinoma.

Treatment decisions also rely on tumour size, grade, lymph-node findings, surgical margins, hormone-receptor status, HER2 status, and any evidence of spread. These features can matter more to the plan than ductal versus lobular origin alone.

Ask the breast team to connect the imaging findings with the biopsy result. Lobular carcinoma can spread through tissue without forming a sharply defined lump, so additional imaging may sometimes help map its extent before surgery. The need for this depends on the individual findings.

Surgery, radiotherapy, endocrine therapy, chemotherapy, and targeted treatment are considered according to disease extent and biology. If hormone-sensitive disease or a high-risk breast lesion is present, the discussion may also include endocrine medicine intended to lower future risk.

Have a clinician assess a new breast or armpit lump, persistent thickening, an unexplained change in breast shape, new nipple inversion, spontaneous bloody discharge, or skin puckering. Invasive ductal and lobular carcinomas can present differently, and the absence of a distinct lump does not rule out a problem.

Someone receiving treatment should promptly report fever, a rapidly worsening wound, new arm swelling, chest pain, breathing difficulty, sudden weakness, or pain that is severe or new. The treatment team can direct urgent assessment based on the symptom and current therapy.

Ask whether the carcinoma is in situ or invasive, ductal or lobular, and whether more than one pattern is present. Confirm the stage, grade, receptor results, imaging–pathology agreement, surgical options, and how the team will monitor the breast and any treated areas over time.